MAPT and tauopathy: PHF1 antibodies recognize both 3R and 4R pathogenic isoforms of tau and were selected because it is widely used for the identification of both astroglial (predominantly 4R) and neuronal (both 3R/4R) tauopathies in CTE [53–55].